Yannis Metaxas

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

Yannis Metaxas, Gareth Rivalland, Laetitia Mauti et al. · Journal of Thoracic Oncology · 2018 · 91 citations · Full text

Medicine, Immunology, Oncology +14

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Yannis Metaxas, Martin Früh, E.I. Eboulet et al. · Annals of Oncology · 2020 · 32 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

Helen Gogas, Urania Dafni, Henry Koon et al. · Journal of Translational Medicine · 2010 · 26 citations · Full text

Life Sciences, Immunology, Oncology +17

Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial

Patrizia Froesch, Michael Mark, Sacha I. Rothschild et al. · Lung Cancer · 2021 · 21 citations

Medicine, Oncology, Pharmacology +12

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2

Michael Mark, Patrizia Froesch, E.I. Eboulet et al. · Cancer Immunology Immunotherapy · 2020 · 18 citations · Full text

Medicine, Oncology, Pharmacology +16